Vertex’s Povetacicept Hits Primary + All Secondary Endpoints in Phase 3 IgAN Trial

Vertex Pharmaceuticals' povetacicept succeeds in Phase 3 RAINIER trial for IgA nephropathy with 52% proteinuria reduction. Positive safety data and FDA submission planned soon.